

Curriculum Vitae

Personal information Catharina Scholl

Work experience

12/2012 - present:

- Scientific employee, Federal Institute for Drugs and Devices, Germany
- since 09/2023: Head of Pharmacogenetics research unit
- Regulatory research in the area of pharmacogenomics and personalized medicine, supervision of the molecular biology research laboratories

10/2009 -11/2012:

- Researcher, Postdoc position, Institute for Pharmacy and Molecular Biotechnology, University of Heidelberg, Germany
- Conducting different research projects in the area of bioanalytics and functional genomics

1/2004-9/2009:

- Researcher, PhD student, Institute for Pharmacy and Molecular Biotechnology, University of Heidelberg, Germany

Education and training

1/2004- 9/2009:

- Doctoral thesis
- Degree: Dr. rer. nat., Institute for Pharmacy and Molecular Biotechnology, University of Heidelberg, Germany

10/2002 -12/2003:

- Practical Training for pharmacists in a public pharmacy
- Degree: Licence to practice as a pharmacist

9/1998- 8/2002:

- Studies of Pharmacy, University of Heidelberg, Germany
- State exam

Additional information

Publications

Selected Publications (2021-2023):

Bergs I, Just KS, **Scholl C**, Dreher M, Stingl JC: Inhalation therapies in COPD - adverse drug reactions impact on emergency department presentations. Eur J Clin Pharmacol 2023, 79(2):219-227.

Seufferlein T, Ettrich TJ, Menzler S, Messmann H, Kleber G, Zipprich A, Frank-Gleich S, Algul H, Metter K, Odemar F et al: Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial. Am J Gastroenterol 2022, 117(6):884-894.

Mbavha BT, Kanji CR, Stadler N, Stingl J, Stanglmair A, **Scholl C**, Wekwete W, Masimirembwa C: Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry. Pharmacogenet Genomics 2022, 32(5):173-182.

Huebner T, Steffens M, **Scholl C**: Molecular Genetic Techniques in Biomarker Analysis Relevant for Drugs Centrally Approved in Europe. Mol Diagn Ther 2022, 26(1):89-103.

Herrlein ML, Schmanke P, Elgner F, Sabino C, Akhras S, Bender D, Glitscher M, Tabari D, **Scholl C**, Stingl J et al: Catch Me if You Can: the Crosstalk of Zika Virus and the Restriction Factor Tetherin. J Virol 2022, 96(4):e0211721.

Fracowiak J, Huebner T, Hess S, Roethlein C, Langner D, Schneider U, Falkenberg F, **Scholl C**, Linder R, Stingl J et al: Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes. Pharmacogenomics J 2022, 22(2):136-144.

Stingl JC, **Scholl C**, Bosch JE, Viviani R: Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain. Translational psychiatry 2021, 11(1):467.

Kemski S, Molitor V, Steffens M, Nümm TJ, Herrmann N, Hornung T, Bieber T, Schumann C, Kächele V, Seufferlein T, **Scholl C**, Stingl J: Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. Oncotarget 2021.

Just KS, **Scholl C**, Boehme M, Kastenmüller K, Just JM, Bleckwenn M, Holdenrieder S, Meier F, Weckbecker K, Stingl JC: Individualized Versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)-Never Change a Running System? Pharmaceuticals 2021, 14(10):1056.

Just KS, Dormann H, Freitag M, Schurig M, Bohme M, Steffens M, **Scholl C**, Seufferlein T, Graeff I, Schwab M et al:

CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System-Results From the ADRED Study. Front Pharmacol 2021, 12(1030):624104.

Huebner T, **Scholl C**, Steffens M: Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe. Diagnostics (Basel) 2021, 11(7).

Glitscher M, Martin DH, Woytinek K, Schmidt B, Tabari D, **Scholl C**, Stingl JC, Seelow E, Choi M, Hildt E: Targeting Cholesterol Metabolism as Efficient Antiviral Strategy Against the Hepatitis E Virus. Cell Mol Gastroenterol Hepatol 2021, 12(1):159-180.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)